2025 Asia-Pacific Antibody Drug Conjugates Contract Manufacturing Revenue Opportunities Report
Description
The 2025 Asia-Pacific Antibody Drug Conjugates Contract Manufacturing Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibody Drug Conjugates Contract Manufacturing by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Antibody Drug Conjugates (ADC) contract manufacturing market in the Asia-Pacific region are WuXi Biologics, Lonza Group, Catalent, and Samsung Biologics. WuXi Biologics leads with state-of-the-art facilities in China, offering end-to-end ADC manufacturing and expanding production capabilities in Singapore. Lonza and Catalent provide advanced biopharmaceutical manufacturing services globally, including ADCs, with extensive experience in clinical and commercial-scale production. Samsung Biologics, based in South Korea, complements the region with high-capacity, cGMP-compliant ADC manufacturing.
Additionally, AstraZeneca's $1.5 billion ADC facility in Singapore is a significant new investment dedicated to ADCs, enhancing capacity and regional presence. Daiichi Sankyo is also expanding its ADC manufacturing footprint with a new $152 million facility in Shanghai, strengthening Asia-Pacific’s role as a hub for ADC innovation and production. These companies leverage supportive regulations, skilled labor, and cost advantages in countries like China, India, Singapore, and South Korea to drive significant growth in ADC contract manufacturing in Asia-Pacific.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibody Drug Conjugates Contract Manufacturing by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Antibody Drug Conjugates (ADC) contract manufacturing market in the Asia-Pacific region are WuXi Biologics, Lonza Group, Catalent, and Samsung Biologics. WuXi Biologics leads with state-of-the-art facilities in China, offering end-to-end ADC manufacturing and expanding production capabilities in Singapore. Lonza and Catalent provide advanced biopharmaceutical manufacturing services globally, including ADCs, with extensive experience in clinical and commercial-scale production. Samsung Biologics, based in South Korea, complements the region with high-capacity, cGMP-compliant ADC manufacturing.
Additionally, AstraZeneca's $1.5 billion ADC facility in Singapore is a significant new investment dedicated to ADCs, enhancing capacity and regional presence. Daiichi Sankyo is also expanding its ADC manufacturing footprint with a new $152 million facility in Shanghai, strengthening Asia-Pacific’s role as a hub for ADC innovation and production. These companies leverage supportive regulations, skilled labor, and cost advantages in countries like China, India, Singapore, and South Korea to drive significant growth in ADC contract manufacturing in Asia-Pacific.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
